Pharming Group (OTCMKTS:PHGUF) Sets New 52-Week High – Here’s Why

Pharming Group NV (OTCMKTS:PHGUF) shares hit a new 52-week high on Tuesday . The company traded as high as $2.17 and last traded at $2.17, with a volume of 5490 shares. The stock had previously closed at $1.65.

Pharming Group Price Performance

The company has a current ratio of 3.16, a quick ratio of 2.39 and a debt-to-equity ratio of 0.46. The company has a market cap of $1.44 billion, a PE ratio of 215.22 and a beta of 0.37. The firm has a 50 day moving average of $1.71 and a two-hundred day moving average of $1.49.

Pharming Group (OTCMKTS:PHGUF) last released its quarterly earnings data on Thursday, November 6th. The biotechnology company reported $0.01 earnings per share for the quarter. The business had revenue of $97.30 million during the quarter, compared to analyst estimates of $80.18 million. Pharming Group had a net margin of 0.30% and a return on equity of 0.46%.

About Pharming Group

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.